Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
To evaluate the efficacy and safety of HG102 for moderate to severe Glabellar Lines, non-inferiority compared to Botox® was confirmed and safety was evaluated.
Epistemonikos ID: 7bc8488e39e1ada4932e90c11a0555c186ec49ee
First added on: Feb 19, 2024